<DOC>
	<DOC>NCT02604823</DOC>
	<brief_summary>This is a study of the efficacy and safety of peginterferon alfa-2a (Pegasys) in naive, interferon- or lamivudine-pretreated participants with HBeAg-positive chronic HBV. Following 48 weeks treatment, there will be a 24 week period of treatment-free follow-up. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult participants between 18 to 65 years of age HBeAgpositive chronic HBV Treatmentnaive, or have received and have not responded to or have relapsed on either conventional interferon or lamivudine therapy. Antiviral or interferonbased therapy for chronic HBV within 6 months of enrollment Coinfection with active hepatitis A, C or D virus or with human immunodeficiency virus (HIV) Evidence of decompensated liver disease Medical condition associated with chronic liver disease other than viral hepatitis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>